Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial

Topline Results from TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan The TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) against investigator’s choice chemotherapy has reported that while the treatment met…

Read MoreFinal Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial